Key facts
- This page summarizes Xiaoming Zhang's Form 4 filing for Vincerx Pharma, Inc. (VINC).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 16 Feb 2022, 15:10.
Xiaoming Zhang - 14 Feb 2022 Form 4 Insider Report for Vincerx Pharma, Inc. (VINC)
- Reporting relationship
- Chief Technology Officer
- Issuer ticker
- VINC
- Reported as of
- 14 Feb 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 16 Feb 2022, 15:10:36 UTC
- Prior SEC filing
- 16 Aug 2021
- Source filing
- View source filing
- Reporting owner signature
- By:/s/ Xiaoming Zhang
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Xiaoming Zhang filed Form 4 for Vincerx Pharma, Inc. (VINC) on 16 Feb 2022.
Change
- Previous filing in this sequence was filed on 16 Aug 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
VINC
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +34,000
- Change %
- Price
- $0.000000
- Shares after
- 34,000
- Date
- 14 Feb 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 34,000
- Exercise price
- $6.26
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Option vests over three years, with 1/3 of the shares vesting on December 23, 2022, and 1/36th of the shares vesting monthly thereafter.